文献速递造血干细胞移植与细胞治疗白血病

受者-供者KIR配体匹配可预防单倍体T细胞充足移植后CMV再激活

Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
PubMed 文献 · Br J Haematol · 2017-05-03

该前瞻性研究分析180例白血病患者供受者HLA和供者KIR分型,评估受训NK细胞对T细胞充足单倍体移植后CMV再激活的预测作用。多因素分析显示供受者KIR配体GVH或HVG方向错配与难治性CMV感染风险升高相关(HR=2.556,95%CI 1.377-4.744,P=0.003)。供受者KIR配体匹配组移植后100天内CMV再激活、难治性CMV感染和CMV病均低于错配组。

要点

  • 供受者KIR配体匹配组移植后100天CMV再激活51.65% vs 错配组75.28%(P=0.012)。
  • 匹配组难治性CMV感染17.58% vs 错配组35.96%(P=0.004),CMV病3.30% vs 11.24%(P=0.024)。
  • 供受者KIR配体错配与难治性CMV感染风险升高相关(HR=2.556,95%CI 1.377-4.744,P=0.003)。

核心结论

  • 供受者KIR配体匹配可能促进NK细胞受训过程,从而增强NK细胞介导的针对CMV再激活的保护作用。

研究设计与样本

  • 前瞻性分析180例白血病患者供受者HLA分型和供者KIR分型,评估受训NK细胞对T细胞充足单倍体造血干细胞移植后CMV再激活的预测作用。

主要发现

  • 多因素分析显示供受者KIR配体移植物抗宿主或宿主抗移植物方向错配与移植后难治性CMV感染增加相关(HR=2.556,95%CI 1.377-4.744,P=0.003)。
  • 供受者KIR配体匹配组移植后100天CMV再激活51.65%(95%CI 46.67-56.62%)vs 错配组75.28%(95%CI 70.87-79.69%),P=0.012。
  • 匹配组难治性CMV感染17.58%(95%CI 13.77-21.40%)vs 错配组35.96%(95%CI 31.09-40.82%),P=0.004。
  • 匹配组CMV病3.30%(95%CI 1.51-5.08%)vs 错配组11.24%(95%CI 8.04-14.43%),P=0.024。
  • 移植后第30天和第100天,KIR配体匹配组受者供者来源NK细胞γ-干扰素表达百分比显著高于GVH或HVG方向错配组(P=0.036和0.047)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Licensed natural killer (NK) cells have been demonstrated to have anti-cytomegalovirus (CMV) activity. We prospectively analysed the human leucocyte antigen typing of donor-recipient pairs and the killer cell immunoglobulin-like receptor (KIR) typing of donors for 180 leukaemia patients to assess the predictive roles of licensed NK cells on CMV reactivation post-T-cell-replete haploidentical stem cell transplantation. Multivariate analysis showed that donor-recipient KIR ligand graft-versus-host or host-versus-graft direction mismatch was associated with increased refractory CMV infection (Hazard ratio = 2·556, 95% confidence interval, 1·377-4·744, P = 0·003) post-transplantation. Donor-recipient KIR ligand matching decreased CMV reactivation [51·65% (46·67, 56·62%) vs. 75·28% (70·87, 79·69%), P = 0·012], refractory CMV infection [17·58% (13·77, 21·40%) vs. 35·96% (31·09, 40·82%), P = 0·004] and CMV disease [3·30% (1·51, 5·08%) vs. 11·24% (8·04, 14·43%), P = 0·024] by day 100 post-transplantation. In addition, the percentage of γ-interferon expression on donor-derived NK cells was significantly higher in the recipients among the recipient-donor pairs with a KIR ligand match compared with that in the recipients among the pairs with a KIR ligand graft-versus-host or host-versus-graft direction mismatch on days 30 and 100 post-transplantation (P = 0·036 and 0·047, respectively). These findings have suggested that donor-recipient KIR ligand matching might promote the NK cell licensing process, thereby increasing NK cell-mediated protection against CMV reactivation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhao XY, Luo XY, Yu XX, et al. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation. Br J Haematol. 2017. PMID: 28466469. doi:10.1111/bjh.14622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。